Research Analysts Set Expectations for Veracyte Q2 Earnings

Veracyte, Inc. (NASDAQ:VCYT) – Stock analysts at William Blair raised their Q2 2025 EPS estimates for shares of Veracyte in a report issued on Tuesday, May 13th. William Blair analyst A. Brackmann now forecasts that the biotechnology company will earn $0.19 per share for the quarter, up from their previous estimate of $0.18. The consensus estimate for Veracyte’s current full-year earnings is $0.68 per share. William Blair also issued estimates for Veracyte’s Q3 2025 earnings at $0.19 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.13 EPS, Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.31 EPS and FY2026 earnings at $0.88 EPS.

A number of other research firms have also issued reports on VCYT. Guggenheim lowered their target price on shares of Veracyte from $45.00 to $37.00 and set a “buy” rating on the stock in a research note on Wednesday, April 9th. Needham & Company LLC lowered their target price on shares of Veracyte from $51.00 to $41.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Stephens reiterated an “overweight” rating and issued a $45.00 target price on shares of Veracyte in a research note on Wednesday, March 26th. Craig Hallum began coverage on shares of Veracyte in a research note on Thursday, March 20th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, UBS Group lowered their target price on shares of Veracyte from $49.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, Veracyte has an average rating of “Moderate Buy” and a consensus target price of $40.90.

Veracyte Stock Performance

Veracyte stock opened at $28.49 on Friday. The company has a market capitalization of $2.23 billion, a P/E ratio of -189.93 and a beta of 2.14. The firm’s fifty day simple moving average is $30.83 and its 200-day simple moving average is $36.98. Veracyte has a 1-year low of $19.73 and a 1-year high of $47.32.

Veracyte (NASDAQ:VCYT) last issued its earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.07. The company had revenue of $118.63 million during the quarter, compared to analyst estimates of $110.73 million. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. During the same quarter last year, the business posted ($0.39) EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of VCYT. Barclays PLC grew its holdings in Veracyte by 138.6% during the third quarter. Barclays PLC now owns 146,402 shares of the biotechnology company’s stock valued at $4,983,000 after purchasing an additional 85,033 shares during the period. Avanza Fonder AB acquired a new position in shares of Veracyte in the fourth quarter valued at approximately $1,379,000. Legal Advantage Investments Inc. acquired a new position in shares of Veracyte in the fourth quarter valued at approximately $250,000. KBC Group NV boosted its holdings in shares of Veracyte by 44.6% in the fourth quarter. KBC Group NV now owns 3,872 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 1,195 shares during the period. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Veracyte in the fourth quarter valued at approximately $262,000.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.